Results 1 to 10 of about 114,789,047 (289)

In Vivo Model of Short-Term Efficacy and Favorable Safety of Botulinum Toxin Type E Compared with Type A [PDF]

Toxins
Botulinum toxin suppresses neurotransmitter release, thereby inhibiting muscle contraction and inducing flaccid paralysis. Botulinum toxin type A (BoNT/A) is widely used for neuromuscular blockade but, upon repeated administration, may cause long-lasting
Jeong-Sun Nam, Daewon Yoon, Yujin Kim, Su-Young Kim, Jae-Young Kim, Yoonkyoung Cha, Joon Seok, Beom Joon Kim   +7 more
doaj   +2 more sources

Iatrogenic botulinum Toxin Type A poisoning with persistent unilateral vocal cord paralysis: a case report and clinical implications [PDF]

Frontiers in Pharmacology
With the continuous advancement of medical aesthetic technologies, botulinum toxin injection has emerged as a prevalent method for wrinkle removal and facial enhancement. However, improper administration can result in botulism incidents.
Shizhao Xiang, Yu Du, Yu Du
doaj   +2 more sources

Botulinum Toxin Type A for Pediatric Torticollis: A Review of Clinical Research [PDF]

Toxins
Pediatric torticollis, predominantly resulting from congenital muscular torticollis, is characterized by unilateral shortening of the sternocleidomastoid muscle, leading to head tilt and limited cervical mobility.
Na-Yoen Kwon, Soo-Hyun Sung, Hyun-Kyung Sung   +2 more
doaj   +2 more sources

Mechanisms of Botulinum Toxin Type A Action on Pain [PDF]

Toxins, 2019
Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic
Zsuzsanna Helyes, Ivica Matak, Lidija Bach-Rojecky   +2 more
exaly   +7 more sources

Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]

Cochrane Database of Systematic Reviews, 2016
This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS, Castelão, M, Rodrigues, FB, Marques, RE, Ferreira, J, Sampaio, C, Moore, AP, Costa, J   +7 more
  +9 more sources

Botulinum toxin preparations: areas for improvement and issues of standardisation

Биопрепараты: Профилактика, диагностика, лечение, 2023
Scientific relevance. Botulinum toxin preparations are a good example of using a deadly toxin as a unique therapeutic agent. However, there are many unresolved issues related to biotechnology, biological activity, interchangeability, and standardisation ...
M. V. Savkina, M. A. Krivykh, L. V. Sayapina, Yu. I. Obukhov, V. P. Bondarev   +4 more
doaj   +1 more source

Prolonged Antipruritic Effect of Botulinum Toxin Type A on Cowhage-induced Itch: A Randomized, Single-blind, Placebo-controlled Trial

Acta Dermato-Venereologica, 2023
Botulinum toxin type A (Botox®) is thought to have antipruritic effects through inhibition of pruritic factors, including acetylcholine, substance P, and glutamate. The aim of this randomized, single-blind, placebo-controlled trial was to test the effect
Leigh A. Nattkemper, Ashley Vander Does, Carolyn M. Stull, Michael J. Lavery, Rodrigo Valdes-Rodriguez, Marlene McGregory, Yiong Huak Chan, Gil Yosipovitch   +7 more
doaj   +1 more source

Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan

eNeurologicalSci, 2021
To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient ...
Ryuji Kaji, Akira Endo, Michiko Sugawara, Mika Ishii   +3 more
doaj   +1 more source

Isolation and typing of Clostridium botulinum from milk powder of an enterprise associated with a case of infant botulism

Zhongguo shipin weisheng zazhi, 2023
ObjectiveThe aim of this study was to detect botulinum toxin and Clostridium botulinum （C.botulinum） in 30 batches of infant formula milk powder obtained from an enterprise and to analyze the whole genome of the strain of C.
LUO Haipeng, QU Hongren, DING Bo, REN Xiu, ZHAO Linna, BAI Jichao, WANG Yaping, LIN Lan, CUI Shenghui   +8 more
doaj   +1 more source

Botulinum toxin type A in treatment of chronic migraine, spasticity and bruxism

Journal of Education, Health and Sport, 2023
Introduction: Nowadays, botulinum toxin has found use in many disease entities such as chronic migraine, spasticity, bruxism and many others. Among serotypes A-E, type A is mainly used in treatment.
Klaudia Kuliga, Katarzyna Dobko, Gabriela Frącz, Agata Glac, Kinga Musz, Natalia Sejnowska, Agnieszka Socha, Agata Surowiec, Kinga Śnieżek, Anna Zając   +9 more
doaj   +1 more source